Thyroid‐stimulating hormone levels after radiotherapy and combined therapy for head and neck cancer | Zendy

Weissler Mark C. | Zendy; Berry Billy W. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Thyroid‐stimulating hormone levels after radiotherapy and combined therapy for head and neck cancer

Author(s) -

Weissler Mark C.,

Berry Billy W.

Publication year - 1991

Publication title -

head and neck

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.012

H-Index - 127

eISSN - 1097-0347

pISSN - 1043-3074

DOI - 10.1002/hed.2880130508

Subject(s) - medicine , radiation therapy , neck dissection , thyroid , thyroidectomy , chemotherapy , hormone , head and neck cancer , thyroid stimulating hormone , thyroid cancer , head and neck , urology , cancer , surgery , oncology

Sixty‐eight patients were studied prospectively with serial thyroid‐stimulating hormone (TSH) levels after radiotherapy for head and neck neoplasms. Overall, 57% of the patients developed elevated TSH levels. Excluding patients with less than 2 years follow‐up, 85% developed an elevated TSH. Ninety‐two percent of patients treated with partial thyroidectomy and radiotherapy developed an elevated TSH. Most TSH elevations occurred within 1 year of treatment. The dose of radiotherapy used and the performance of hemithyroidectomy were related to the development of elevated TSH levels ( p < 0.05). The performance of radical neck dissection, gender, hyperfractionated radiotherapy, and the use of chemotherapy were not related to the development of an elevated TSH ( p > 0.05).

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research